awmsg logo



perampanel (Fycompa®)


Reference No. 1219

Publication date:
31/07/2013


Last review date:
30/08/2016

Appraisal information

perampanel (Fycompa®) 2 mg film-coated tablet
perampanel (Fycompa®) 4 mg film-coated tablet
perampanel (Fycompa®) 6 mg film-coated tablet
perampanel (Fycompa®) 8 mg film-coated tablet
perampanel (Fycompa®) 10 mg film-coated tablet
perampanel (Fycompa®) 12 mg film-coated tablet


Company: Eisai Ltd
BNF category: Central nervous system
NMG meeting date: 10/04/2013
AWMSG meeting date: 08/05/2013
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1313
Ministerial ratification: 29/07/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Perampanel (Fycompa®) is recommended as an option for restricted use within NHS Wales. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. Perampanel (Fycompa®) should be restricted to treatment of patients whose seizures are still uncontrolled with first adjunctive therapy, within its licensed indication as adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Perampanel (Fycompa®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download